Non-celiac gluten sensitivity : time for sifting the grain by L. Elli et al.
8221 July 21, 2015|Volume 21|Issue 27|WJG|www.wjgnet.com
Luca Elli, Leda Roncoroni, Maria Teresa Bardella, Center for 
Prevention and Diagnosis of Celiac Disease, Gastroenterology 
and Endoscopy Unit, Department of Pathophysiology and 
Transplantation, Università degli Studi di Milano. Fondazione 
IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 
Milano, Italy
Author contributions: Elli L, Roncoroni L and Bardella MT 
contributed equally to this paper.
Conflict-of-interest statement: The authors declare no conflict 
of interests.
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Correspondence to: Luca Elli, MD, PhD, Center for Prevention 
and Diagnosis of Celiac Disease, Gastroenterology and Endoscopy 
Unit, Department of Pathophysiology and Transplantation, 
Università degli Studi di Milano. Fondazione IRCCS Ca’ Granda 
Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milano, 
Italy. dottorlucaelli@gmail.com
Telephone: +39-2-55033384
Fax: +39-2-55033664
Received: January 23, 2015
Peer-review started: January 23, 2015
First decision: March 10, 2015
Revised: April 1, 2015
Accepted: May 27, 2015
Article in press: May 27, 2015
Published online: July 21, 2015
Abstract
In the last few years, a new nomenclature has been 
proposed for the disease induced by the ingestion of 
gluten, a protein present in wheat, rice, barley and 
oats. Besides celiac disease and wheat allergy, the most 
studied forms of gluten-related disorders characterized 
by an evident immune mechanism (autoimmune in 
celiac disease and IgE-mediated in wheat allergy), a 
new entity has been included, apparently not driven 
by an aberrant immune response: the non-celiac 
gluten sensitivity (NCGS). NCGS is characterized by 
a heterogeneous clinical picture with intestinal and 
extraintestinal symptoms arising after gluten ingestion 
and rapidly improving after its withdrawal from the diet. 
The pathogenesis of NCGS is largely unknown, but a 
mixture of factors such as the stimulation of the innate 
immune system, the direct cytotoxic effects of gluten, 
and probably the synergy with other wheat molecules, 
are clues for the complicated puzzle. In addition, the 
diagnostic procedures still remain problematic due 
to the absence of efficient diagnostic markers; thus, 
diagnosis is based upon the symptomatic response to a 
gluten-free diet and the recurrence of symptoms after 
gluten reintroduction with the possibility of an important 
involvement of a placebo effect. The temporary with-
drawal of gluten seems a reasonable therapy, but 
the timing of gluten reintroduction and the correct 
patient management approach are have not yet been 
determined.
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Core tip: Gluten-related disorders are extremely re-
levant in gastroenterologic practice, and their pre-
valence has increased in recent decades. Besides 
celiac disease and allergy, the newly born non-celiac 
gluten sensitivity is still an obscure syndrome with an 
unknown pathogenesis and important clinical concerns 
regarding diagnosis and patient management.
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INTRODUCTION
Wheat is a basic staple of the human diet, especially 
in Western countries where wheat-containing food 
dominates the menu. Since the start of agriculture 
in Mesopotamia about 10000 years ago, wheat has 
sustained mankind’s development and health up to 
the present day[1]. This apparently contrasts with 
the selection of a genetic background susceptible to 
immune reactions against gluten [i.e., celiac disease 
(CD)], the HLA DQ2 haplotype[2]. The development 
of adverse reactions against wheat and, in particular, 
against gluten, is supposed to be concomitant with 
the very moment humans started its ingestion. The 
first description of a patient affected by CD is ascribed 
to Areteus of Cappadocia, who in the 2nd century AD 
reported a case of chronic diarrhea and malabsorption. 
However, only at the end of the 19th century, Samuel 
Gee scientifically described the celiac syndrome in 
childhood and in the 1950s, Willem Dicke identified 
gluten as the environmental agent of CD[3]. Since 
then, the scientific community’s interest concerning 
the effects of gluten on humans and the mechanisms 
underpinning gluten-induced intestinal and systemic 
damage has increased[4-6]. Nowadays, CD is considered 
an autoimmune disorder affecting about 1% of the 
worldwide population[7,8]. A different mechanism 
is involved in the allergic reaction to wheat (wheat 
allergy): a condition affecting 4% of the population 
with heterogeneous intestinal, respiratory, and 
cutaneous symptoms[6]. In addition to the food allergy 
against wheat, the other major forms of wheat allergy 
are baker’s asthma and wheat-dependent exercise-
induced anaphylaxis, which can lead to important 
anaphylactic reactions[9]. 
Recently, a third clinical syndrome has been 
introduced under the generic umbrella of gluten-related 
disorder, or non-celiac gluten sensitivity (NCGS), which 
apparently involves neither the allergic nor autoimmune 
mechanisms or a specific genetic background, as in 
CD[4]. Thus, gluten or other wheat components are 
supposedly the environmental factors that induce a 
wide range of gluten-related diseases with different 
pathogenic pathways, which globally affect a large 
proportion of the population[4,10].
NCGS AND ITS POSSIBLE 
PATHOMECHANISMS
NCGS is a clinical syndrome characterized by both 
intestinal and extraintestinal symptoms, which are 
responsive to gluten (wheat) withdrawal from the diet. 
The mechanisms by which gluten induces symptoms 
in NCGS are largely unknown, but their difference 
from those present in CD and wheat allergy appears 
clear. Although data is scant and conflicting, one can 
hypothesize that a multifactorial process is at the base 
of the NCGS symptomatic onset. The involvement of 
the innate immune system, a direct cytotoxic effect 
of gluten and gliadin, and the involvement of different 
target organs and other proteic components of wheat 
can be all implicated.
Firstly, the study by Sapone et al[11] demonstrated 
in a series of NCGS subjects reporting different 
gastrointestinal symptoms that intestinal permeability 
and adaptive immune responses are not involved in 
the process. In fact, by using the lactulose/mannitol 
test and investigating the main components of tight 
junctions (zonulin and claudins), the authors found 
no alterations, this fact excluding the presence of a 
“leaky gut” as in CD or other intestinal inflammatory 
conditions. The concomitant duodenal increase of toll-
like receptor-2 and the significant reduction of the 
T-regulatory cell marker FOXP3 compared to healthy 
subjects and CD patients suggested a stimulation 
of the innate immune system that does not involve 
the interferon γ pathway. In the duodenal histology 
of NCGS, a slight increase of γ and δ intraepithelial 
lymphocytes was reported. The data collected on the 
absence of an adaptive immune response stimulation 
seems to be confirmed by another study that 
investigated the effect of a gluten-containing diet in 
patients affected by a diarrhea-type irritable bowel 
syndrome (IBS)[12]. In contrast with the previous 
studies, an alteration of gut permeability was reported 
in these patients, especially in subjects carrying a 
CD-compatible genetic background (i.e., HLA DQ2). 
However, the definitive exclusion of the adaptive 
immune system is not possible. Based on the findings 
published by Brottveit et al[13], who explored and 
compared the initial mucosal immunologic events 
in CD and NCGS subjects before and after a gluten 
challenge, an increase of interferon γ and heat shock 
protein 27 levels after gluten challenge was evidenced 
together with an increased density of intraepithelial 
lymphocytes, this latter independent from the gluten 
challenge. Differently, other authors failed to identify 
any gliadin-related immunologic alteration in the 
duodenal mucosa of NCGS patients[14].
Besides the possible alteration of the immune 
system, gluten presents some peculiar biologic 
properties that induce intestinal damage[15]. Different in 
vitro studies on two- and three-dimensional cell cultures 
(mainly enterocytes) demonstrated that the treatment 
with gluten and gliadin induces alterations of the main 
cellular homeostatic processes. Cellular morphology 
and motility[16,17] and cytoskeleton organization and 
intercellular contact through the tight junction proteins 
are all altered[18,19]. Treated cells present a reduced 
viability due to the stimulation of apoptosis and a 
reduction of synthesis of nucleic acids (DNA and RNA) 
and proteins[20]. Moreover, the oxidative balance is 
disrupted by a decrease of reduced glutathione and 
thiols[18,21].
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While the researchers’ attention is focused on 
gluten, other molecules also contained in wheat may 
be involved in the NCGS symptoms. Among them, 
the amylase trypsin inhibitor enzymatic family is a 
known trigger of the toll-like receptor-4 pathway of the 
innate immune system, stimulating the release of pro-
inflammatory cytokines in cells from CD and non-CD 
patients and biopsies[22]. Other authors have indicated 
that the fermentable oligosaccharides, disaccharides, 
monosaccharides and polyols-present in wheat 
(fructans) and other foods and known as FODMAPs-are 
important factors in causing unspecific gastrointestinal 
symptoms (especially bloating). These poorly absorbed 
short-chain carbohydrates are fermented in the colon 
with gas release, the resulting intestinal distension 
being at the base of reported symptoms. In a placebo-
controlled, crossover rechallenge study, Biesiekierski et 
al[23] found no evidence of a specific dose-dependent 
effect of gluten in patients with suspected NCGS 
undergoing a low FODMAPs diet. Although graved by 
an important nocebo effect, their data suggest that 
NCGS might be confused with FODMAP sensitivity, and 
gluten might be only a cofactor (or a confounder) when 
looking for the origin of gastrointestinal symptoms. 
In a recent study, a low FODMAP diet was effective in 
controlling gastrointestinal symptoms in patients with 
intestinal bowel disease[24], thus supporting its use as a 
first-line therapy. However, the data from the reported 
studies are extremely heterogeneous and even scant 
in the case of amylase trypsin inhibitor, thus making 
their interpretation difficult. The main bias is caused by 
the absence of a clear diagnostic flowchart for NCGS 
as all the studies simply enrolled patients clinically 
responding to a period of gluten-free dieting without 
excluding the placebo effect. 
HOW MANY PATIENTS WITH NCGS ARE 
THERE AND WHICH SYMPTOMS DO 
THEY REPORT?
Subjects with NCGS claim a variety of intestinal and/or 
extra-intestinal symptoms, similar to those occurring 
in patients affected by CD or IBS[25]. Symptoms occur 
after gluten ingestion; they improve/disappear when 
gluten is withdrawn from the diet or recur within a few 
hours or days on gluten challenge. 
In a recent Italian, multicenter prospective survey 
of 486 subjects with symptomatic benefit from a 
gluten-free diet (62% of these subjects underwent 
intestinal biopsy to exclude CD), the large majority 
of patients reported more than two associated 
gastrointestinal or extraintestinal symptoms[10]. The 
most frequent intestinal symptoms (> 80%) were 
bloating and abdominal pain, while more than 50% 
of patients reported diarrhea, 27% alternating bowel 
habits, and 24% constipation. Also, epigastric pain was 
frequent and followed, with decreasing prevalence, 
by nausea, aerophagia, gastroesophageal reflux 
disease, and aphthous stomatitis. In this study, as in 
many other studies on NCGS, systemic extraintestinal 
symptoms were frequently present: tiredness, lack of 
well-being, and neuropsychiatric symptoms such as 
headache, anxiety, “foggy mind”, arm/leg numbness, and 
depression. Additional extraintestinal manifestations 
were as reported: muscle or joint pain, weight 
loss, dermatitis, and skin rash. Looking at the data 
regarding gluten withdrawal, NCGS is suspected in 
children (with fatigue apparently as their most frequent 
systemic symptom) and in adults, with a higher 
prevalence in females than in males[6,26]. Additionally, 
there are reports that NCGS is more common in 
families with a history of CD[26-29].
There is some overlap between IBS and NCGS. In 
fact, in patients fulfilling the Rome Ⅲ criteria for IBS, 
mainly in those with diarrhea, both predominant and 
in mixed form, NCGS has been diagnosed in a high 
percentage of cases: these have been sub-grouped as 
having gluten-sensitive IBS[30-32]. Similarly, in patients 
affected by allergic disorders, a high prevalence of NCGS 
has been reported (77/262 patients), thus confirming 
the need for a clearer definition of both the syndrome 
and the effects of gluten on the gastrointestinal tract[33].
An objective approach to NCGS diagnosis is not 
available to date, as significant serologic and histologic 
markers are lacking; thus, the epidemiology of the 
NCGS disorder is quite approximate and not based on 
powerful studies. The reported prevalence of NCGS in 
the current literature varies between 0.6% and 6%. 
The former prevalence rate results from the National 
Health and Nutrition Examination Survey program, 
based on interviews and medical examinations carried 
out by general practitioners[34], while the latter rate is 
the outcome of the experience by the Tertiary Center 
for Celiac Research at the University of Maryland[6]. At 
present, we should consider as affected by NCGS only 
those subjects who have been extensively studied to 
exclude CD or wheat allergy and have responded to 
a blind placebo-controlled gluten challenge, therefore 
excluding self-diagnosed self-treated subjects. 
HOW CAN WE DIAGNOSE AND TREAT 
NCGS?
The main problem concerning NCGS is the absence of 
a set of standardized diagnostic criteria. The clinical 
picture of NCGS seems very unspecific. Although 
some allergic manifestations (urticaria, asthma, labial 
edema, etc.) strongly suggest the presence of an 
IgE-mediated disorder, the presence of abdominal 
discomfort, evacuation disturbances, foggy mind, 
chronic fatigue, and unspecific skin manifestations 
do not help clinicians in any differential diagnosis. 
As a result, when NCGS is suspected, the first step 
is represented by the exclusion of other disorders, 
especially CD and wheat allergy. Serologic negativity to 
anti-transglutaminase IgA and anti-wheat component 
IgE antibodies and/or the absence of a duodenal 
atrophy at duodenal histology and skin reaction during 
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a prick test, are necessary pre-requisites.
Despite the absence of reliable NCGS biomarkers, 
some serologic and/or histologic alterations have been 
reported: (1) anti-gliadin antibodies IgG class could be 
present in 50% of patients with suspected NCGS[27]; 
(2) cytometric basophil activation is positive in 66% 
of patients responding to a wheat blind challenge 
associated to duodenal intraepithelial lymphocytosis 
and eosinophil infiltration of duodenum and colon[35,36]; 
and (3) mild duodenal intraepithelial lymphocytosis 
could be present in about 50% of NCGS cases, 
suggesting a microscopic enteritis[10,36,37]. 
Once alternative causes of a patient’s clinical status 
have been excluded, the second step is to focus on a 
link between symptoms and gluten ingestion with an 
on/off mechanism. Typically, symptoms would arise 
rapidly or at least after a few hours from the ingestion 
of gluten-containing food and would disappear 
“instantly” once gluten is withdrawn from the diet. 
This passage meets some criticism. Firstly, the period 
of gluten exclusion to ascertain the symptomatic 
response is not standardized, therefore, it is not clear 
how long the gluten-free diet should be maintained in 
absence of any clinical response. Secondly, the gluten-
free dietary regimen during the proof period (if you 
pardon the pun) should be kept absolutely strict-the 
same way as for CD-to facilitate nutritional control. 
Thirdly, how should a gluten-free diet response be 
checked and measured, and how great should the 
symptomatic improvement be in order to define a 
patient responsive to gluten exclusion? Because of 
the absence of reliable biomarkers altered by gluten 
ingestion, a symptomatic trend can be measured 
using scores (as the gastrointestinal symptom rating 
scale) validated for functional diseases or visual 
analogue scales[38]. The quantification of symptomatic 
improvement is at the base of a common definition 
of “gluten-free diet response”. Although necessary, a 
response to a gluten-free diet would be insufficient 
to define a patient as gluten sensitive, due to the 
possibility of a placebo effect, which is known to be 
present in functional diseases[39]. Thus, a third step is 
required in order to eliminate or reduce the impact of 
the placebo effect in the diagnostic process. To reach 
this goal, a double- or at least single-blind challenge 
should be proposed to patients while they are on their 
gluten-free diet, to make evident the symptomatic 
onset during the blind assumption of gluten in a sort of 
n-of-1 process[40]. The problems to be solved here are: 
What dosage of gluten? Which vehicle should be used? 
How long should the challenge last? Which method to 
use for symptoms quantification?
POTENTIAL MANAGEMENT OPTIONS 
AND CONCLUSIONS
Once the diagnosis of NCGS is reasonably reached, the 
management and follow-up of patients is completely 
obscure. A logical approach is to undertake a gluten-
free dietary regimen for a limited period (e.g., six 
months), followed by the gradual reintroduction of 
gluten. During the gluten-free diet, the ingestion 
of prolamine peptide (gliadin)-derived from wheat, 
rye, barley, oats, bulgur, and hybrids of these cereal 
grains-should be avoided. Rice, corn, and potatoes 
have been the typical substitutes, but nowadays other 
different cereals and pseudocereals, such as amaranth, 
buckwheat, manioc, fonio, teff, millet, quinoa, and 
sorghum, can be used. After some period on a gluten-
free diet, the reintroduction of gluten can start with 
cereals of low gluten content (e.g., oats). In addition, 
einkorn farro (Triticum monococcum) can be used, 
having no direct in vitro or ex vivo toxicity and low (7%) 
gluten content[41]. 
Chronically, gluten-free-diet periods can be 
administered during symptomatic relapses as a sort 
of “on-demand” therapy. NCGS is a clinical syndrome 
hampered by many obscure sides (summarized in 
Table 1). Its pathogenesis and clinical presentation 
are not clear, and the diagnostic flowchart and patient 
management are not standardized. However, in the 
Name and definition Pathogenesis Prevalence Diagnosis Treatment
Non-celiac gluten/wheat sensitivity is 
an intestinal/extraintestinal syndrome 
responsive to gluten withdrawal in 
absence of CD and WA
Multi-factorial, including 
innate immunity and direct 
cytotoxic effects of gluten
Ranging from 3% to 5%, 
though specific studies 
are lacking
Via placebo-controlled blind 
gluten challenge
No data are available 
for guidance
Other molecules are 
potentially involved: 
Amylase trypsin inhibitor, 
FODMAPs
Prior exclusion of celiac disease 
and allergy
An on-demand 
gluten-free regimen 
should be considered
AGA IgG, IELs, basophil 
activation and eosinophil 
duodenal/colon infiltration are 
potential biomarkers
AGA: Anti-gliadin antibodies; CD: Celiac disease; FODMAP: Fermentable oligosaccharides, disaccharides, monosaccharides, and polyols; IELs: 
Intraepithelial lymphocytes; WA: Wheat allergy.
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epidemiologic dimension, the possibility to spare a 
large number of patients undergoing a drug-based 
therapy with side effects and costs is intriguing and 
makes NCGS a hot topic in gastroenterology. 
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